Fig. 1


Number of Cells
1
2
0
10^0
10^1
10^2
10^3
Fluorescence Intensity

Fig. 2


Number of Cells
3
0
10^0
10^1
10^2
10^3
Fluorescence Intensity

Fig. 3


Number of Cells
← 4
0
10⁰
10¹
10²
10³
Fluorescence Intensity

Fig. 4


120
100
80
60
40
20
0
% Viability
0 0.001
0.01
0.1
1
10
Ig (μg/ml)
NOK1
NOK2
NOK3
Fas-Ig

Fig. 5


Cell
Sup
NOK-1
cIg
NOK-1
cIg
kD
94
67
43
30
20.1
14.4

Fig. 6


0.5
0.4
0.3
0.2
0.1
0.0
OD490
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0
Concentration of soluble
Fas ligand (ng/ml)

Fig. 7


Soluble Fas ligand (ng/ml)
0
1
2
3
4
5
Normal
IM
SLE
apla
GVHD
VAHS
Hepatitis

Fig. 8


Counts
0
60
120
180
240
300
10^0
10^1
10^2
10^3
10^4
Fluorescence Intensity
Control
NOK1
NOK2
NOK3

Fig. 9


50
40
30
20
10
0
% 51Cr release
Effector ← hFasL/L5178Y → ← mFasL/L5178Y →
Target WR ← hFas/WR → WR ← hFas/WR →
mAb (-) (-) NOK (-) (-) NOK
1 2 3 1 2 3

Fig. 10


100bp
CONTROL VH
NOK VH
1 2 3 4
CONTROL VL
NOK VL
1 2 3 4

Fig. 11



Fig. 12



Fig. 13


CDR1
CDR2
CDR3
NOK1VH .amino 1:VQLQESGPELVKPGASVKISCKASGYAF--SSSWMNWVKQRPGKGLEWIGRIYPGDGDTN 58
NOK2VH .amino 1:VQLQQSGAELVRPGTSVKMSCKAAGYTF--TNYWIGWVKQRPGHGLEWIGYLYPGGLYTN 58
NOK3VH .amino 1:VKLQESGPELVKPGASVKISCKASGYAF--SSSWMNWVKQRPGKGLEWIGRIYPVNGDTN 58
NOK4VH .amino 1:VQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYW-NWIRQFPGNKLEWMG-YISYDGSNN 58
NOK5VH .amino 1:VQLQESGAEPAKPGASVKMSCKASGYTF--TTYWMHWVKQRPGQGLEWIGYINPSSGYTE 58
NOK1VH .amino 59:DNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSYYYDGSPW-FTYWGQGTTVT 117
NOK2VH .amino 59:YNEKFKGKATLTADTSSSTAYMQLSSLTSEDSAIYYCARYRDYD-YAMDY--WGQGTTVT 115
NOK3VH .amino 59:YNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCA-T---DGY-WYFDVWGQGTTVT 113
NOK4VH .amino 59:YNPSLKNRISITRDTSKNQFFLKLNSVTTEDTATYYCA-VYYYDG--SSFDYWGQGTTVT 115
NOK5VH .amino 59:YNQKFKDKATLTADKSSSTAYMQLISLTSEDSAVYYCARRGNY--YYFDY--WGQGTTVT 114
NOK1VH .amino 118:VSS 120
NOK2VH .amino 116:VSS 118
NOK3VH .amino 114:VSS 116
NOK4VH .amino 116:VSS 118
NOK5VH .amino 115:VSS 117

Fig. 14


CDR1
CDR2
NOK1VL .amino 1:DIQMTQSPSSLSASLGDRVTISCRASQDISNY-----LNWYQQKPDGTVKLLIYYTSRLH 55
NOK2VL .amino 1:DVLMTQTPLSLPVNIGDQASISCKSTKSLLNSDGFTYLGWCLQKPGQSPQLLIYLVSNRF 60
NOK4VL .amino 1:DIVLTQSPASLAVSLRQRATISCRASEGVDSY-GISFMHWYQQKPGQPPKLLIYRASYLK 59
NOK5VL .amino 1:DVLMTQTPKFLPVSAGDRVTMTCKASQS-V---G-NNVAWYQQKPGQSPKLLIYYTSNRY 55
CDR3
NOK1VL .amino 56:SGVPSRFSGSGSGTDYSLTISNLEPEDIATYFC-QQYSEFPWTFGGGTKLEIKR 108
NOK2VL .amino 61:SGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSNY-LPLTFGSGTKLEIKR 113
NOK4VL .amino 60:SGVPARFSGSGSRTDFTLTIDPVEADDAATYYC-QQNNEDPWTFGGGTKLEIKR 112
NOK5VL .amino 56:TGVPDRFTGSGSGTDFTFTISSVQVEDLAVYFC-QQHYSSPYTFGSGTKLE--- 105

Fig. 15


FR1
CDR1
FR2
CDR2
NOK1VH.amino 1:QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGRIYPGDGDTND 60
NOK2VH.amino 1:QVHLQQSGAELVRPGTSVKMSCKAAGYTFTNYWIGWVKQRPGHGLEWIGYLYPGGLYTNY 60
NOK3VH.amino 1:QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWIGRIYPVNGDTNY 60
FR3
CDR3
FR4
NOK1VH.amino 61:NGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSYYYDGSPW-FTYWGQGTLVTVSA 121
NOK2VH.amino 61:NEKFKGKATLTADTSSSTAYMQLSSLTSEDSAIYYCARYRDYD-YAMDY--WGQGTSVTVSS 119
NOK3VH.amino 61:NGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCA-T---DGY-WYFDVWGAGTTVTVSS 117

Fig. 16

```
                          FR1                 CDR1              FR2        CDR2
NOK1VL.amino  1:DIQMTQTTSSLSASLGDRVTISCRASQDISNY-----LNWYQQKPDGTVKLLIYYTSRLHS  56
NOK2VL.amino  1:DVVLTQTPLSLPVNIGDQASISCKSTKSLLNSDGFTYLGWCLQKPGQSPQLLIYLVSNRFS  61
NOK3VL.amino  1:NIVMTQSPKSMSMSVGERVTLSCKASENVDIY-----VSWYQQKPEQSPKLLIYGTSNRYT  56

                          FR3                 CDR3      FR4
NOK1VL.amino 57:GVPSRFSGSGSGTDYSLTISNLEPEDIATYFCQQYSEFPWTFGGGTKLEIKR          108
NOK2VL.amino 62:GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQSNYLPLTFGSGTKLEIKR          113
NOK3VL.amino 57:GVPDRFTGSGSATDFTLTISNVQAEDLSDYYCVQSYSYPWTFGGGTKLEIKR          108
```

Fig. 17



Fig. 18


300
250
200
150
100
50
0
Counts
Cell: mFasL/BHK
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 19


250
200
150
100
50
0
Counts
L5178Y
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 20


hFasL/L5178Y
Counts
300
240
180
120
60
0
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 21


mFasL/L5178Y
Counts
300
240
180
120
60
0
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 22


Balb/c mouse origin
300
240
180
120
60
0
Counts
0
10^1
10^2
10^3
10^4
Fluorescence Intensity

Fig. 23


B6 mouse origin
250
200
150
100
50
0
Counts
0
10^1
10^2
10^3
10^4
Fluorescence Intensity

Fig. 24


DBA mouse origin
250
200
150
100
50
0
Counts
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 25


C3H mouse origin
250
200
150
100
50
0
Counts
0
10¹
10²
10³
10⁴
Fluorescence Intensity

Fig. 26


100
80
60
40
20
0
Cytotoxic activity %
No addition of antibody
Addition of antibody
10 μ g/ml
Target cell : WR19L
hFas/WR19L

Fig. 27


100
80
60
40
20
0
Cytotoxic activity %
129
BK1
POK
T16D
E/T=20
10
20
30
40
KAY-10 (μ g/ml)